If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ® (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Are there any dose modifications for hematologic adverse events?
Dose modifications are recommended for low absolute neutrophil and platelet counts.
Dose Modifications for Hematologic Adverse Events
Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue treatment with pirtobrutinib.1
Dose modifications are recommended for
- absolute neutrophil count
- < 1 to 0.5 x 109/L with fever and/or infection or
- < 0.5 x 109/L lasting 7 or more days
- platelet count
- < 50 to 25 x 109/L with bleeding or
- < 25 x 109/L.1
Recommended Dose Modifications of Pirtobrutinib for Hematologic Adverse Reactions Based on a Starting Dosage of 200 mg summarizes the recommended dose modifications for hematologic adverse events.
If any of the following adverse reactions... |
Occur for the... |
Then... |
And... |
|
first time |
interrupt pirtobrutinib until recovery to grade 1 or baseline |
restart at original dose level (200 mg daily). |
second time |
restart at 100 mg daily. |
||
third time |
restart at 50 mg daily. |
||
fourth time |
discontinue pirtobrutinib |
do not restart. |
aDose modification is not recommended for asymptomatic lymphocytosis.
Enclosed Prescribing Information
Reference
1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: December 12, 2022